JPS5758626A - Carcinostatic agent - Google Patents

Carcinostatic agent

Info

Publication number
JPS5758626A
JPS5758626A JP13397780A JP13397780A JPS5758626A JP S5758626 A JPS5758626 A JP S5758626A JP 13397780 A JP13397780 A JP 13397780A JP 13397780 A JP13397780 A JP 13397780A JP S5758626 A JPS5758626 A JP S5758626A
Authority
JP
Japan
Prior art keywords
formula
orally
cancers
agent
compound expressed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP13397780A
Other languages
Japanese (ja)
Other versions
JPS639493B2 (en
Inventor
Setsuo Takeuchi
Mutsuyuki Kochi
Akira Kawarada
Shinichiro Esumi
Kazuya Sasaki
Tsuneo Saida
Masao Sakasai
Yukio Inoue
Tadasu Yamamoto
Ban Sanai
Takaharu Sekine
Koji Amamiya
Katsumasa Saga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaken Pharmaceutical Co Ltd
RIKEN Institute of Physical and Chemical Research
Original Assignee
Kaken Pharmaceutical Co Ltd
Kaken Chemical Co Ltd
RIKEN Institute of Physical and Chemical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharmaceutical Co Ltd, Kaken Chemical Co Ltd, RIKEN Institute of Physical and Chemical Research filed Critical Kaken Pharmaceutical Co Ltd
Priority to JP13397780A priority Critical patent/JPS5758626A/en
Publication of JPS5758626A publication Critical patent/JPS5758626A/en
Publication of JPS639493B2 publication Critical patent/JPS639493B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

PURPOSE: A carcionstatic agent, containing an N-formlyamino acid compound as an active constituent, capable of exhibiting a high susceptibility to cancerated cells cancerated by SV40 carcinogenic viruses, having low toxicity, and administrable orally or parenterally.
CONSTITUTION: A carcinostatic agent containing an N-formylamino acid compound expressed by the formula (R is amino acid residue), e.g. N-formylglycine or N- formyl-L-tyrosine, as an active constituent. The compound expressed by the formula can be formulated into a water-soluble suspension or oily pharmaceutical in the form of subcutaneous or intravenous injection pharmaceutical or formulated into a tablet, fine granules, etc. which may be administrered orally. The dose of the agent is 0.5W5,000mg/kg/day orally, and the upper limit of an injection is 100mg/kg/day. Most of the conventional carcinostatic agents have high susceptibility to transplanted cancers; however, the compound expressed by the formula has an activity against cancers which are induced by SV40 viruses and may be said to be artificial (induced) initial cancers. The mode of action thereof is different from the conventionalone, and the clinical effect is expectable.
COPYRIGHT: (C)1982,JPO&Japio
JP13397780A 1980-09-26 1980-09-26 Carcinostatic agent Granted JPS5758626A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP13397780A JPS5758626A (en) 1980-09-26 1980-09-26 Carcinostatic agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP13397780A JPS5758626A (en) 1980-09-26 1980-09-26 Carcinostatic agent

Publications (2)

Publication Number Publication Date
JPS5758626A true JPS5758626A (en) 1982-04-08
JPS639493B2 JPS639493B2 (en) 1988-02-29

Family

ID=15117493

Family Applications (1)

Application Number Title Priority Date Filing Date
JP13397780A Granted JPS5758626A (en) 1980-09-26 1980-09-26 Carcinostatic agent

Country Status (1)

Country Link
JP (1) JPS5758626A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114953A (en) * 1990-11-21 1992-05-19 University Of Florida Treatment for tissue ulceration
US5183900A (en) * 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
US5239078A (en) * 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
US5268384A (en) * 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
ITRM20110278A1 (en) * 2011-06-06 2012-12-07 Cavallari Ivan PHARMACEUTICAL COMPOSITION INCLUDING FORMALDEHYDE, A SOURCE OF FORMILE IONS AND ITS USES IN MEDICAL FIELD.

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63134194U (en) * 1987-02-24 1988-09-02
JPS63160387U (en) * 1987-04-08 1988-10-20

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114953A (en) * 1990-11-21 1992-05-19 University Of Florida Treatment for tissue ulceration
US5183900A (en) * 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
US5239078A (en) * 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
US5268384A (en) * 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
US5696147A (en) * 1990-11-21 1997-12-09 Glycomed, Inc. Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
ITRM20110278A1 (en) * 2011-06-06 2012-12-07 Cavallari Ivan PHARMACEUTICAL COMPOSITION INCLUDING FORMALDEHYDE, A SOURCE OF FORMILE IONS AND ITS USES IN MEDICAL FIELD.

Also Published As

Publication number Publication date
JPS639493B2 (en) 1988-02-29

Similar Documents

Publication Publication Date Title
JPS5671074A (en) 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
ES480850A1 (en) Hydantoin compounds, their preparation and pharmaceutical formulations containing them.
JPS5692846A (en) Tetrapeptide derivative and its preparation
JPS5758626A (en) Carcinostatic agent
JPS567716A (en) Preventive and remedy for cerebral angiospasm
JPS5791997A (en) 5'-o-acylnucleoside and its preparation
JPS57136579A (en) Thiazolylurea derivative, its preparation, and pharmaceutical composition containing the same
IE821258L (en) Anti-herpes medicaments
JPS5489036A (en) Remedy and preventive for hypersensitivity to light
JPS5735515A (en) Immunoregulating agent
JPS5630917A (en) Preventive and remedy for hepatitis
JPS5470428A (en) Carcinostatic agent
GB1096983A (en) 5-nitrothiazolyl-dioxo-diazacycloalkanes and process for their manufacture
JPS56131554A (en) Novel d-glutamic acid derivative, its preparation, and immunizing agent containing said derivative as effective component
JPS5668611A (en) Novel antiallergic agent
JPS57128625A (en) Carcinostatic
JPS57126461A (en) Novel guanidino compound and its preparation
JPS5536454A (en) Novel immunosuppressive agent
JPS5758618A (en) Carcinostatic agent
JPS54125663A (en) Carcinostatic agent and novel compound having carcinostatic activity
JPS55129265A (en) Interferon-inducing agent
JPS5758619A (en) Carcinostatic agent
JPS5721400A (en) Novel fortimicin derivative
JPS54135738A (en) Novel aminobenzoic acid-n-d-mannoside and drugs comprising it
JPS5527152A (en) Immunizator containing 1-piperazinecarboxyamide derivative as effective ingredient